SEBI Reg. Investment Advisor

Download App
Help Center Pricing
Money Works 4 Me Logo MoneyWorks4Me
Login Get Free Account
Sign Up

MoneyWorks4Me

Log In Sign Up Schedule Free 15‑min Call
Login Get Free Account
Sign Up

INVESTMENT INSIGHTS

Check Before You Invest : Novelix Pharmaceuticals Ltd

BSE: 536565 NSE: ISIN: INE314I01036
  |   Sector:  Miscellaneous   |   Industry:  Trading

Snapshot

Q.1 Which industry/sub-sector does Novelix Pharmaceuticals Ltd belong to?
Novelix Pharmaceuticals Ltd belongs to the Miscellaneous sector, operating specifically within the Trading segment.
Q.2 Is Novelix Pharmaceuticals Ltd a good quality company?
Novelix Pharmaceuticals Ltd is a quality company, based on a 10 year financial track record.
Q.3 Is Novelix Pharmaceuticals Ltd undervalued or overvalued?
Novelix Pharmaceuticals Ltd appears Somewhat overvalued, as its key valuation ratios are above with their past averages.
Q.4 Is Novelix Pharmaceuticals Ltd a good buy now?
Novelix Pharmaceuticals Ltd is not a good buy now, based on weak price trend analysis suggesting prices may fall. However, you need to check its quality and valuation before making a decision

Performance Analysis

Q.1 Revenue growth of Novelix Pharmaceuticals Ltd?
Novelix Pharmaceuticals Ltd revenue growth is 628% for FY-2025 , which is above its 5 year CAGR of 97.2% , indicating faster growth.
Q.2 Gross Profit margin of Novelix Pharmaceuticals Ltd?
Novelix Pharmaceuticals Ltd Gross profit margin which is the profit after deduction of direct costs, is 0.5% for FY-2025 , which is above its 5 year median of -0.2% , indicating increasing margins.
Q.3 Operating Profit Margin of Novelix Pharmaceuticals Ltd?
Novelix Pharmaceuticals Ltd Operating Profit Margin which is the profit after deduction of all operating costs, is 0.51% for FY-2025 , which is above its 5 year median of -36.86% indicating increasing margins.
Q.4 Net Profit Margin of Novelix Pharmaceuticals Ltd?
Novelix Pharmaceuticals Ltd Net Profit Margin is 0.28% for FY-2025 , is above with its 5 year median of -4.27%, indicating increasing margins.
Current Level Historic Median
Gross Profit Margin 0.5 -0.2
Operating Profit Margin 0.51 -36.86
Net Profit Margin 0.28 -4.27
Q.5 Return on Asset of Novelix Pharmaceuticals Ltd?
Novelix Pharmaceuticals Ltd Return on Asset is 0.49(x), which is above its 5 year historical median of -0.83(x), indicating improved asset utilization efficiency.
Q.6 Return on Equity (ROE) of Novelix Pharmaceuticals Ltd?
Novelix Pharmaceuticals Ltd Return on equity is 0.68% for FY-2025 , which is above its historical median of -0.83%, indicating the business is making better use of its shareholders capital.
Q.7 Return on capital employed (ROCE) of Novelix Pharmaceuticals Ltd?
Novelix Pharmaceuticals Ltd Return on capital employed is 1% for FY-2025 , which is below its estimated weighted average cost of capital(WACC) 14%, indicating value preservation.
Q.8 Cash conversion cycle of Novelix Pharmaceuticals Ltd?
Novelix Pharmaceuticals Ltd Cash conversion cycle is 62 , below its historical median of 94 , indicating improved working capital management. However, you need to compare this with its peers in the industry.
Current Level Historic Median
Asset Turnover 1.78 0.2
ROE 0.68 -0.83
ROCE 1 -0.81
Cash Conversion Cycle 62 94
Q.9 Debt to Equity ratio of Novelix Pharmaceuticals Ltd?
Novelix Pharmaceuticals Ltd Debt-to-Equity ratio is 0.00 , which is lower with the industry average of 0.03 , indicating lower debt levels in the industry.
Q.10 Debt to cash flow from operations of Novelix Pharmaceuticals Ltd?
Novelix Pharmaceuticals Ltd Debt to cash flow from operations is 0 , which is at a healthy level, indicating the business is able to service its debt comfortably.

Ownership & governance

Q.1 Promoter shareholding and pledge status of Novelix Pharmaceuticals Ltd?
Promoters hold 51.98% of the Novelix Pharmaceuticals Ltd, with 0.00% of their stake pledged, indicating no pledge risk.

Peer comparison (industry-wise, mcap)

Q.1 Revenue growth of Novelix Pharmaceuticals Ltd vs industry peers?
Novelix Pharmaceuticals Ltd revenue CAGR is 97.20% , compared to the industry median CAGR of 0% , indicating faster growth and gaining its market share.
Profit Metrics
Current Level Industry Median
Revenue 30.7 13.3
Gross Profit 0.2 0.4
Operating Profit - 0
Net Profit - 0.3
Operating Efficiency
Current Level Industry Median
Asset Turnover 1.78 0.5
ROE 0.68 2.03
ROCE 1 3.6
Cash Conversion Cycle 62.48 41

Valuation & price assessment

Q.1 Stock return of Novelix Pharmaceuticals Ltd over the last decade?
Over the last 9 years, the stock has delivered a CAGR of 21.4% based on the current price.
Q.2 What return has the stock given over the last decade?
9Y 5Y 3Y 1Y
Share Price 21.4% 58.2% 82.1% 109.8%
Q.3 Valuation ratios of Novelix Pharmaceuticals Ltd vs historical?
The current P/E is higher that its historical median.
Q.4 How do the current valuation ratios measure up against the historic numbers and the current industry numbers?
Valuation Ratios Current Historic Median Industry Median
Price to Earnings 66.34 0.00 21.75
Price to Book 2.47 0.89 1.55
Price to Sales 0.95 7.69 1.87
EV to EBITDA 48.67 -3.17 13.67

Check more companies

1. Aditya Infotech
2. Aegis Logistics
3. Redington
4. RRP Semiconductor
5. Honasa Consumer
6. Cello World
7. Lloyds Enterprises
8. MMTC
9. Jeena Sikho Life
10. SG Mart
2026 ©The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me® is a registered trademark of The Alchemists Ark Pvt. Ltd.

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×